Glaxo Sues XenoPort Over Contract for Restless-Leg Medicine
This article is for subscribers only.
A GlaxoSmithKline Plc unit sued XenoPort Inc. in federal court in Delaware, seeking a ruling that it properly promoted the restless-leg medicine Horizant in the U.S.
Glaxo Group of Middlesex, England, and Santa Clara, California-based XenoPort agreed to collaborate on Horizant starting in 2007 and the drug was approved by the U.S. Food and Drug Administration last year, according to court papers.